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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to oat and 
barley grain fibre and increase in faecal bulk (ID 819, 822) pursuant to 
Article 13(1) of Regulation (EC) No 1924/2006
1 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 
3 
European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims in 
relation to oat and barley grain fibre and increase in faecal bulk. The scientific substantiation is based 
on the information provided by the Member States in the consolidated list of Article 13 health claims 
and references that EFSA has received from Member States or directly from stakeholders. 
The food constituent that is the subject of the health claim is oat and barley grain fibre. The Panel 
considers that oat and barley grain fibre is sufficiently characterised in relation to the claimed effect. 
The claimed effect is “gut health”. The target population is assumed to be the general population. In 
the context of the clarifications provided by Member States and the references provided, the Panel 
assumes that the claimed effect refers to the improvement of bowel function by increasing faecal bulk. 
The Panel considers that an increase in faecal bulk may be a beneficial physiological effect.  
In weighing the evidence, the Panel took into account that the role of cereal grain fibre in increasing 
faecal bulk in humans is well established, that the mechanisms by which cereal grain fibre exerts the 
claimed effect are known, that oat fibre has a significant bulking effect in humans, and that a similar 
effect can be expected from barley grain fibre taking into account the similar composition of oat and 
barley fibre.  
The  Panel  concludes  that  a  cause  and  effect  relationship  has  been  established  between  the 
consumption of oat and barley grain fibre and an increase in faecal bulk. 
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The Panel considers that in order to obtain the claimed effect a food should be at least “high in fibre” 
from oats or barley as per Annex to Regulation (EC) No 1924/2006. The target population is the 
general population.  
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INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The  consolidated  list  of  health  claims  pursuant  to  Article  13  of  Regulation  (EC)  No  1924/2006
4 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all hea lth claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for  evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve as 
clarification to the originally provided information. The information provided in the consolidated list 
for the health claims which are the subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
1.  Characterisation of the food/constituent (ID 819, 822) 
The food constituent that is the subject of the health claim is barley grain fibre and oat grain fibre.  
Oat (Avena sativa L.) and barley (Hordeum vulgare L.) are cereals which produce grains that contain 
dietary fibre, constituting about 10-12 % of oat grain and about 11–15 % of barley grain. Beta-glucans 
are the main components of the soluble dietary fibre in oat and barley grain. The composition of the 
insoluble dietary fibre in oat and barley is similar to the dietary fibre of other cereal grains, and 
consists mainly of cellulose, hemicelluloses and lignin (Baik and Ulrich, 2008; Mälkki and Virtanen, 
2001; Sadiq Butt et al., 2008). 
The Panel considers that the food constituent, oat and barley grain fibre, which is the subject of the 
health claim, is sufficiently characterised in relation to the claimed effect. 
2.  Relevance of the claimed effect to human health (ID 819, 822) 
The  claimed  effect  is  “gut  health”.  The  Panel  assumes  that  the  target  population  is  the  general 
population. 
In the context of the clarifications provided by Member States and the references provided, the Panel 
assumes that the claimed effect refers to the improvement of bowel function by increasing faecal bulk.  
The Panel considers that an increase in faecal bulk may be a beneficial physiological effect. 
3.  Scientific substantiation of the claimed effect (ID 819, 822) 
The evidence provided by consensus opinions/reports of authoritative bodies and reviews shows that 
there is good consensus on the role of cereal grain fibre, and in particular of cereal bran, in increasing 
faecal  bulk  in  humans  (Cummings  et  al.,  2001;  EFSA  Panel  on  Dietetic  Products  Nutrition  and 
Allergies (NDA), 2010a, 2010b, 2011). 
It is well established that the bulking effect of cereal fibre is closely related to the physico-chemical 
properties of the fibre, and thereby to the degree of fermentation by the gut microbiota in the large 
intestine. Insoluble dietary fibre is fermented to a lesser extent than soluble dietary fibre, and thereby 
leads  to  an  increase  in  faecal  bulking  per  se.  The  bulking  effects  of  soluble  dietary  fibre  are 
determined by the higher extent of fermentation, and thus an increase in the bacterial mass in faeces 
(bacteria contain about 80 % water) (Cummings et al., 2001).  
                                                       
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5  EFSA Panel on Dietet ic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. Oat and barley grain fibre and increase in faecal bulk  
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For cereal fibres, the average increase in faecal output per gram of dietary fibre consumed by humans 
is estimated to be 3.4 g for oat bran or oats, compared to 3.3 g for corn meal or corn bran and 5.4 g for 
wheat bran, and 3.5 g for cellulose (Cummings, 2001). Although no value was provided for barley 
grain fibre, the similarity in composition of dietary fibre in oats and barley suggests a similar effect of 
barley grain fibre on faecal bulk.  
In weighing the evidence, the Panel took into account that the role of cereal grain fibre in increasing 
faecal bulk in humans is well established, that the mechanisms by which cereal grain fibre exerts the 
claimed  effect  are  known,  that  oat fibre  has  a  significant  bulking  effect in  humans,  and  that  the 
similarity in composition of dietary fibre in oats and barley suggests a similar effect of barley grain 
fibre on faecal bulk.  
The  Panel  concludes  that  a  cause  and  effect  relationship  has  been  established  between  the 
consumption of oat and barley grain fibre and an increase in faecal bulk. 
4.  Panel comments on the proposed wording (ID 819, 822) 
The  Panel  considers  that  the  following  wordings  reflect  the  scientific  evidence:  “Oat  grain  fibre 
contributes to an increase in faecal bulk”. “Barley grain fibre contributes to an increase in faecal bulk”. 
5.  Conditions and possible restrictions of use (ID 819, 822) 
The Panel considers that in order to obtain the claimed effect, a food should be at least “high in fibre” 
from oats or barley as per Annex to Regulation (EC) No 1924/2006. The target population is the 
general population.  
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
  The food constituent, oat and barley grain fibre, which is the subject of the health claim, is 
sufficiently characterised in relation to the claimed effect. 
  The  claimed  effect  is  “gut  health”.  The  target  population  is  assumed  to  be  the  general 
population.  In  the  context  of  the  clarifications  from  Member  States  and  the  references 
provided,  the  Panel  assumes  that  the  claimed  effect  refers  to  the  improvement  of  bowel 
function by increasing faecal bulk. Increase in faecal bulk may be a beneficial physiological 
effect. 
  A cause and effect relationship has been established between the consumption of oat and 
barley grain fibre and an increase in faecal bulk. 
  The following  wordings  reflect the  scientific  evidence:  “Oat  grain fibre  contributes  to  an 
increase in faecal bulk”. “Barley grain fibre contributes to an increase in faecal bulk”. 
  In order to obtain the claimed effect, a food should be at least “high in fibre” from oats or 
barley as per Annex to Regulation (EC) No 1924/2006. The target population is the general 
population.  
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-1606 and 
EFSA-Q-2008-1609.).  The  scientific  substantiation  is  based  on  the  information  provided  by  the 
Member States in the consolidated list of Article 13 health claims and references that EFSA has 
received from Member States or directly from stakeholders. 
The  full  list  of  supporting  references  as  provided  to  EFSA  is  available  on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. Oat and barley grain fibre and increase in faecal bulk  
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The  Regulation  1924/2006  on  nutrition  and  health  claims  made  on  foods
6  (hereinafter  "the 
Regulation") entered into force on 19
th January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health". 
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a)  the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b)  psychological and behavioural functions; or 
c)  without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be: 
(i)  based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January  2008  accompanied  by  the  conditions  applying  to  them  and  by  references to  the  relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3). 
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
7  
Foods are commonly involved in many different functions
8 of the body, and for one single food many 
health claims may therefore be scientifically true.  Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to a 
single food is scientifically pertinent. 
It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect. 
                                                       
6 OJ L12, 18/01/2007 
7 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
8 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).  Oat and barley grain fibre and increase in faecal bulk  
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SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific data, 
and by weighing the evidence, and shall demonstrate the extent to which: 
(a)  the claimed effect of the food is beneficial for human health, 
(b)  a cause and effect relationship is established between consumption of the food and the 
claimed  effect  in  humans  (such  as:  the  strength,  consistency,  specificity,  dose-
response, and biological plausibility of the relationship), 
(c)  the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d)  the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of the 
application for authorisation of health claims consistent criteria for the potential sources of scientific 
data. Such sources may not be available for all health claims. Nevertheless it will be relevant and 
important that EFSA comments on the availability and quality of such data in order to allow the 
regulator to judge and make a risk management decision about the acceptability of health claims 
included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not enough 
to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. Moreover, 
the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially affect identified 
functions in the body in a way which is relevant to health. Although an appreciation of the beneficial 
effect in relation to the nutritional status of the European population may be of interest, the presence or 
absence of the actual need for a nutrient or other substance with nutritional or physiological effect for 
that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic or 
cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of the 
body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function  of  the  joints"  may  not  sufficiently  do  so,  whereas  a  claim  such  as  "Substance  X  helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which specifies 
this by using the word "flexibility". Oat and barley grain fibre and increase in faecal bulk  
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The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore be 
specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings should 
be avoided. To this end, wordings like "strengthens your natural defences" or "contain antioxidants" 
should be considered as well as "may" or "might" as opposed to words like "contributes", "aids" or 
"helps".  
In addition, for functions affected by a large number of dietary factors it should be considered whether 
wordings such as "indispensable", "necessary", "essential" and "important" reflects the strength of the 
scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects: 
  Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
  Whether the beneficial effect of the food on the function is substantiated by generally accepted 
scientific evidence by taking into account the totality of the available scientific data, and by 
weighing the evidence. In this context EFSA is invited to comment on the nature and quality 
of the totality of the evidence provided according to consistent criteria. 
  The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent. 
In addition, EFSA should consider the claimed effect on the function, and provide advice on the extent 
to which: 
  the claimed effect of the food in the identified function is beneficial. 
  a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
  where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
  the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
  the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: Oat and barley grain fibre and increase in faecal bulk  
 
11  EFSA Journal 2011;9(6):2249 
  on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. Oat and barley grain fibre and increase in faecal bulk  
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of  the  food/food  constituent,  a  positive  assessment  of  its  safety,  nor  a  decision  on  whether  the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. Oat and barley grain fibre and increase in faecal bulk  
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APPENDIX C 
Table 1. Main entry health claims related to oat and barley grain fibre, including conditions of use 
from similar claims, as proposed in the Consolidated List. 
 
ID  Food or Food constituent  Health Relationship  Proposed wording 
819  Barley grain fibre.  Gut health. 
Clarification provided 
Promotes bowel function. 
Helps to maintain normal 
bowel function. 
Promotes gut functioning. 
Conditions of use 
-  Bakery products which contain 6g/100g of barley grain fibre, beta-glucan of barley grain 
fibre ≥3g/daily serving. Processing of the product does not influence the impact of beta-
glucan fibre on the gut, only the amount of beta-glucan is significant.  
Comments from Member States 
Health relationship defined 
ID  Food or Food constituent  Health Relationship  Proposed wording 
822  Oat grain fibre. 
Clarification provided 
Oat grain fibre. 
Gut health. 
Clarification provided 
Promotes bowel function. 
Helps to maintain normal 
bowel function. 
Promotes gut’s functioning. 
Clarification provided 
Promotes gut’s functioning. 
Conditions of use 
-  Bakery products with ≥3g/100g of beta-glucan of oat grain fibre. Amount: 6g/100g of oat 
grain fibre. Processing of the product does not affect the impact of beta-glucan fibre on the 
guts, only the amount of beta-glucan is significant. 
  Comments from Member States 
Health relationship defined 
 